Five Questions Concerning Managing Hepatitis C in the Justice System
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 32 (2) , 323-345
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Merck
- NSF (1722906, 1722665)
This publication has 32 references indexed in Scilit:
- Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2013
- Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisonsBMJ Open, 2013
- Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United StatesPLOS ONE, 2013
- Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United StatesClinical Infectious Diseases, 2013
- Economic model of a birth cohort screening program for hepatitis C virusHepatology, 2011
- Diversity of Release Patterns for Jail Detainees: Implications for Public Health InterventionsAmerican Journal of Public Health, 2011
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- Elevated prevalence of hepatitis C infection in users of United States veterans medical centersHepatology, 2004
- Treatment of Chronic Hepatitis C in a State Correctional FacilityAnnals of Internal Medicine, 2003
- Characteristics of Intravenous Drug Users by History of Arrest and Treatment for Drug UseJournal of Nervous & Mental Disease, 1992